framycetin

General

**Off Market Drug**
This medication is no longer available in the United States. Information provided here is for reference purposes only.

Canada-Approved Medicine

This monograph describes a medication approved for use in Canada by the Therapeutic Products Directorate, a division of Health Canada’s Health Products and Food Branch. The medication is not approved by the United States Food and Drug Administration; however, a similar formulation carrying a different generic or brand name might be available in the US.

Pronunciation:
fray-mye-see-tin

Trade Name(s)

  • SoframycinCanadian Tradename

Ther. Class.
anti-infectives

Pharm. Class.
aminoglycosides

Indications

Local treatment of ocular infections due to susceptible organisms including blepharitis, conjunctivitis, corneal injuries, corneal ulcers, meibomianitis, ocular infections, following foreign body removal (prevention of infection).

Action

Inhibits protein synthesis in susceptible bacteria by binding to ribosomal subunits; not active against fungi, viruses, and most anaerobic bacteria. Active against Staphylococcus aureus, the proteus group of bacteria, coliforms, and Pseudomonas aeruginosa.

Therapeutic Effect(s):

Erradication/prevention of infection.

Pharmacokinetics

Absorption: Poorly absorbed following oral administration. Minimal systemic absorption following ophthalmic use.

Distribution: Unknown.

Metabolism and Excretion: Unknown.

Half-life: Unknown.

TIME/ACTION PROFILE

ROUTEONSETPEAKDURATION
ophthrapidunknown1–6 hr (longer for opth ointment)

Contraindication/Precautions

Contraindicated in:

  • Hypersensitivity (cross-sensitivity with other aminoglycosides may occur).

Use Cautiously in:

  • OB: has been used safely;
  • Lactation: has been used safely;
  • Pedi: Safe and effective use not established.

Adverse Reactions/Side Effects

Local: allergic cutaneous reactions

Misc: overgrowth of nonsusceptible organisms (prolonged use)

* CAPITALS indicate life-threatening.
Underline indicate most frequent.

Interactions

Drug-Drug

None noted.

Route/Dosage

Ophth: (Adults) Ophthalmic solution–1–2 drops every 1–2 hr acutely for 2–3 days, then 1–2 drops 3–4 times daily; ophthalmic ointment–apply 2–3 times daily or use at bedtime if solution has been used during the day.

Availability

Ophthalmic solution: 5 mg/ml in 8-mL bottles

Ophthalmic ointment: 5 mg/g in 5-g tubes

In Combination with: phenylephrine (Soframycin Nasal Spray), gramicidin (Soframycin Skin Ointment)

Assessment

  • Assess the degree of pain and visual impairment.

Potential Diagnoses

Implementation

  • When administering avoid touching any part of eye. Wash hands and wear gloves to administer ophthalmic medication. See medication administration techniques for administration instructions.
  • Ophth: Drops: Apply 1 or 2 drops to affected eye every 1–2 hrs for first 2–3 days. Dose may then decrease to 1 or 2 drops to affected eye 3 or 4 times daily.
  • Ophth: Ointment: Apply ointment to affected eye 2 or 3 times per day, or at bedtime if solution has been used during day.

Patient/Family Teaching

Instruct patient on proper technique for applying drops or ointment.

Evaluation/Desired Outcomes

Resolution of signs and symptoms of eye infection.

framycetin is a sample topic from the Davis's Drug Guide.

To view other topics, please or purchase a subscription.

Anesthesia Central is an all-in-one web and mobile solution for treating patients before, during, and after surgery. This collection of drug, procedures and test information is derived from Davis’s Drug, MGH Clinical Anesthesia Procedures, Pocket Guide to Diagnostic Tests, and MEDLINE Journals. Complete Product Information.